-
Shanghai: The seventh batch of 42 drugs has price caps, affecting a large number of pharmacies
Time of Update: 2022-09-09
According to the information pushed by the Sunshine platform and the "red and yellow reminder line", combined with the relevant stipulations of the medical insurance service agreement of the designated pharmacy, the retail price is uploaded independently and the price effective date is filled in .
-
The price of Radix ginseng fell, and the pressure on the cost of raw materials of Jiangzhong Pharmaceutical was relieved!
Time of Update: 2022-09-09
com, in recent years, the Chinese patent medicine market for the terminal digestive system of physical pharmacies in China has maintained steady growth, with sales exceeding 14 billion yuan in 2020 and a new high in 2021, with a year-on-year increase of 3.
-
Huahai is up!
Time of Update: 2022-09-09
At present, Huahai Pharmaceutical has 15 innovative drugs (12 Class 1 new drugs) Among them, 2 new drugs are in phase III clinical stage and are expected to be marketed; 38 varieties have been reviewed (15 first), and a total of 18 varieties have won bids for national centralized procurement; 26 new categories of reported products are under review, of which 3 No first imitation (including first imitation of dosage form) has been approved yet .
-
Under the continuous increase of policies, China's medical device industry will have broad room for growth
Time of Update: 2022-09-07
At the same time, in the future development, the subdivision mainly based on in vitro diagnostic reagents, orthopedic medical devices, cardiovascular medical devices, medical imaging equipment and high-value consumables may become the focus of the state's encouragement of development and industry investment.
-
This week, 11 new stocks were subscribed, 2 were pharmaceutical new stocks!
Time of Update: 2022-09-07
1871 million yuan, and the net profit attributable to the shareholders of the parent company after deducting non-recurring gains and losses was 36.
1871 million yuan, and the net profit attributable to the shareholders of the parent company after deducting non-recurring gains and losses was 36.
-
In the first half of the year, medical and health investment and financing slowed down, and these segments are still sought after
Time of Update: 2022-09-07
For example, in May, anti-tumor drug developer Maitong Biologics announced the completion of a round of financing, the company is mainly engaged in the development of new small molecule targeted anti-tumor drugs with metabolic enzymes related to tumorigenesis as the target, etc.
-
Domestic CAR-T therapy has entered the "harvest period" one after another, and the sales volume in the first half of the year has varied greatly
Time of Update: 2022-09-07
Among them, Fosun Kate, a subsidiary of Fosun Pharma, was approved for listing in June 2021, and Agironse Injection is the first CAR-T cell therapy product approved for marketing in China, and the approved indications are for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after receiving second-line or above systemic treatment.
-
The long-term development of the Chinese medicine sector is optimistic, and these segments are being focused on
Time of Update: 2022-09-07
According to the combing point of view, more than half of the pharmaceutical companies' net profit attributable to the mother achieved year-on-year growth, such as Dong'e Ejiao, Tablet Zai Zhen, Jiuzhitang and so on.
-
The performance of CRO companies has increased significantly, and the industry boom will continue
Time of Update: 2022-09-07
It is understood that as of August 30 this year, 29 A-share CXO (pharmaceutical outsourcing services, including CDMO and CRO) companies have disclosed semi-annual reports, and 21 companies have increased their net profit year-on-year, accounting for more than 70% .
-
The number of people vaccinated with the third dose of the new crown vaccine in Japan accounts for 64.8% of the total population of the country.
Time of Update: 2022-09-07
medical conditions Japan's Ministry of Health, Labor and Welfare said on the 5th that starting from the 19th of this month, it will provide about 30 million doses of bivalent new crown vaccines produced by Pfizer and Modena in the United States.
-
The survival rate of children with cancer in South Africa is not optimistic
Time of Update: 2022-09-07
Lewis pointed out that the main factors such as the delay in the diagnosis and treatment of children with cancer and the insufficient number of specially trained paediatric health workers have made it difficult to satisfy the current treatment of children with cancer in South Africa.
-
Notice on Carrying out Information Maintenance of Traditional Chinese Medicine Formula Granules
Time of Update: 2022-09-06
4. Maintenance requirements (1) When the product information of traditional Chinese medicine formula granules obtained by the drug regulatory department for the listing/inter-provincial sales record number is added, deleted or changed, it should be maintained in time through the "Dynamic Maintenance of Medical Insurance Business Coding Standards" window .
-
Off-label medication reissue!
Time of Update: 2022-09-06
In 2021, the Shandong Pharmaceutical Association compiled the "Shandong Province Expert Consensus on Drugs Beyond the Instructions for Use (2021 Edition)", which will be updated in 2022 after a year of practice and feedback based on clinical needs and actual drug use .
-
The performance of traditional Chinese medicine has maintained good growth, and the advantages of exclusive varieties are expected to be further highlighted
Time of Update: 2022-09-06
It is reported that in the traditional Chinese medicine industry, the net profit attributable to the mother of longshen Rongfa, Guangyuyuan, Dong'e Ejiao and Jiaying Pharmaceutical has increased by more than 100% year-on-year, and the net profit attributable to the mother of Baiyun Mountain, China Resources Sanjiu, Katazai Zhen, Yiling Pharmaceutical and Jichuan Pharmaceutical has ranked first, all of which exceed 1 billion yuan.
-
The AI pharmaceutical boom is gradually receding, how to survive the winter under the challenges?
Time of Update: 2022-09-06
The AI pharmaceutical boom is gradually receding According to the data, AbSci Company was officially listed on July 22, 2021, and its main business is to use synthetic biology and deep learning AI technology to identify, screen and expand the production of new drug candidates.
-
The medical equipment track ushered in a wave of listings, and many companies embarked on the road to IPO
Time of Update: 2022-09-06
According to public information, Mingfeng Medical focuses on high-end medical imaging equipment, and its main products and services include the sales and after-sales maintenance services of large-scale medical imaging equipment such as CT and PET/CT, of which the company has listed 18 CT products and 3 PET/CT products.
-
This drug has great potential and is expected to revolutionize the entire antidiabetic drug market!
Time of Update: 2022-09-06
Eli Lilly further upgraded with the introduction of Dulaglutide, which is administered once a week and was approved by the FDA in 2014 for the treatment of type 2 diabetes.
-
This hot targeted drug field is waiting for domestic pharmaceutical companies to grab the food market!
Time of Update: 2022-09-06
From the perspective of domestic research and development progress, the local pharmaceutical company with faster research and development progress is Hengrui, whose self-developed JAK1 inhibitor SHR0302 is being carried out in phase III clinical trials for the treatment of atopic dermatitis, ulcerative colitis and alopecia areata.
-
Hengrui and Heyi won the first imitation of ophthalmic drugs, and the 7 exclusive review varieties are eye-catching!
Time of Update: 2022-09-06
The diquafosol sodium eye drops of Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, and the lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical are the first imitations in China .
-
Since the listing of 3 pharmaceutical stocks, the stock price has been eye-catching, with an increase of more than 200 times!
Time of Update: 2022-09-06
【Pharmaceutical network pharmaceutical stock market】Recently is the semi-annual report disclosure period of listed companies, data show that in the field of pharmaceutical biology, as of August 25, more than 280 pharmaceutical and biological companies have issued semi-annual reports, nearly 60% of the companies have achieved performance growth, and nearly 30 companies have doubled their net profit attributable to the mother.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
